#South Korea #Seoul #Mosaic 3D #IMCAS 2026 #Cynosure Lutronic

Cynosure Lutronic and the Future of Aesthetic Medicine

As the global landscape of aesthetic medicine continues to evolve, Cynosure Lutronic is at the forefront of innovation. Recently, the company announced a significant milestone: the successful acquisition of CE marking for their groundbreaking technology, Mosaic 3D™. This achievement, as part of the European Union’s Medical Device Regulation (MDR), indicates a promising future for advanced fractional resurfacing solutions.

The Implications of CE Marking

The CE marking serves as a confirmation that Mosaic 3D™ meets the stringent requirements of the European market for medical devices. This approval opens doors not only for expanding its presence across Europe but also enhances its reputation within the aesthetic community. Following successful introductions in various international markets, the momentum behind Mosaic 3D™ is bolstered by positive clinical feedback and growing interest from leading experts worldwide.

What is Mosaic 3D™?

Mosaic 3D™ is touted as the next evolution in non-ablative fractional lasers. This cutting-edge technology is designed to deliver higher energy levels while covering a wider treatment area. Its patient safety features prioritize comfort and minimize downtime, ensuring an improved aesthetic experience. Here are some of its standout features:

• - 3D Controlled Chaos Technology™: This innovative technology optimizes the distribution and depth of microbeams, enhancing treatment efficiency by reducing overall thermal heating.

• - Integrated Cooling System: This feature allows practitioners to treat sensitive areas around the eyes and mouth more effectively, reducing discomfort and potential side effects.

• - Versatility in Treatment: Mosaic 3D™ stimulates neocollagenesis and neoelastinogenesis in the mid-dermis, offering comprehensive skin revitalization including enhanced skin texture and radiance.

Global Clinical Validation

Leading dermatologists and aesthetic practitioners have been instrumental in validating the clinical efficacy of Mosaic 3D™. Experts such as Dr. Guy Erlich from Israel, Professor Merete Haedersdal from Denmark, and Dr. Tatiana Kuznechenkova from the UAE have reported positive patient outcomes and treatment adaptability. Dr. Erlich noted, “Mosaic 3D™ elevates the control of fractional resurfacing to new heights, providing exceptional results and treatment flexibility.”

Anticipation for IMCAS 2026

The excitement surrounding Mosaic 3D™ will culminate at the upcoming IMCAS 2026 congress, where it will be highlighted extensively. Cynosure Lutronic is scheduled to conduct a scientific symposium titled “Introducing Mosaic 3D™, Redefining Non-Ablative Fractional Lasers (NAFL)”. This symposium promises to delve into clinical data, treatment protocols, and real-world experiences from practitioners using Mosaic 3D™.

The event, which takes place on January 30, 2026, at 3:45 PM in room 351 on level 3, aims to foster discussions on the latest advancements in laser technology and its implications for patient care.

Looking Ahead

Cynosure Lutronic has been a leader in energy-based medical devices for over 30 years, continually evolving to meet the needs of practitioners and patients alike across the globe. Their commitment to evidence-based innovation plays a crucial role in enhancing patient care outcomes in the aesthetic medicine industry.

With the approval of Mosaic 3D™, Cynosure Lutronic not only strengthens its market position but also catalyzes further advancements in non-invasive aesthetic treatments. The future indeed looks promising for both Cynosure Lutronic and the patients who stand to benefit from their innovative technologies.

For further information, please contact Cynosure Lutronic, EMEA and LATAM Sales Director, Fleur Requena.